Father attributes son’s delayed access to medication to bureaucracy

A father, striving to extend his son’s life, has asserted that the crucial medication his son requires is freely accessible, but “bureaucracy is standing in the way”. Ben, a resident of Henley-on-Thames, is contending with Duchenne Muscular Dystrophy (DMD), which is described as a severe and advancing condition that causes muscle degeneration. Alex, the father of the 11-year-old, indicated that a novel medication, which holds the potential to decelerate his son’s incurable illness, is currently unavailable because of “budgetary and cost constraints” within the regional NHS. Oxford University Hospitals NHS Foundation Trust (OUH) communicated that it was “engaging actively” in dialogues concerning the prospective therapy. An OUH representative stated: “We understand that this is a very worrying and difficult time for Ben and his family. The provision of Givinostat is under discussion and review nationally.” “We are engaging actively in these discussions, including with partner organisations.” Alex mentioned that Ben had reached a stage in his life where he was “starting to feel his body fail him”. Duchenne Muscular Dystrophy (DMD) is an inherited genetic disorder characterized by a progressive weakening of muscles, which results in escalating disability. Individuals affected by this condition typically have a life expectancy extending only into their 20s or 30s, as reported by the NHS. Alex remarked: “One of the most tragic things about it is that these boys will learn a whole lot of life skills around physical movement and the ability to get around, and then as they progress through they start to lose the ability to walk.” “It’s an all round challenge for Ben to deal with on a daily basis, but he does it with a big smile on his face, so we’re very proud of him.” Givinostat, a drug that received approval for usage in America earlier this year, represents a potential therapeutic option for DMD, as stated by Muscular Dystrophy UK. This anti-inflammatory medication is presently undergoing evaluation by UK regulatory bodies and is accessible prematurely, via the NHS, for individuals who fulfill stringent criteria. Regional NHS trusts are required to submit individual applications to participate in the Early Access Programme, a process Alex asserted is “not happening here [in Oxfordshire]”. He conveyed that a “short sighted” approach to expenses was being favored over the lasting benefits of a “better quality of life for these boys who are marginalized because their rare disease”. He commented: “We have been on our Duchenne journey with Ben since 2017, and in that time, there has not been a single drug come to market and available, funded on the NHS, that Ben could access.” “Here is one that he would benefit him, and the frustration is really, really, really high because with boys with Duchenne, time is muscle.” “The longer we wait for something, the less chance there is that they’ll be able to access it.” Updates from BBC Oxfordshire are available on Facebook, X (Twitter), or Instagram. Copyright 2024 BBC. All rights reserved. The BBC disclaims responsibility for the content of external sites. Details on our approach to external linking are provided.